CALA Calithera Biosciences, Inc. Stock Quote

CALA [NASD]

Index	-	P/E	-	EPS (ttm)	-1.39	Insider Own	0.72%	Shs Outstand	70.56M	Perf Week	-0.33%
Market Cap	231.07M	Forward P/E	-	EPS next Y	-0.97	Insider Trans	-0.44%	Shs Float	70.05M	Perf Month	-45.22%
Income	-89.30M	PEG	-	EPS next Q	-0.32	Inst Own	81.70%	Short Float	4.59%	Perf Quarter	-27.32%
Sales	-	P/S	-	EPS this Y	-27.30%	Inst Trans	0.63%	Short Ratio	2.41	Perf Half Y	-44.81%
Book/sh	1.74	P/B	1.71	EPS next Y	26.00%	ROA	-56.60%	Target Price	5.00	Perf Year	-58.67%
Cash/sh	1.78	P/C	1.68	EPS next 5Y	-	ROE	-66.60%	52W Range	2.46 - 8.18	Perf YTD	-39.31%
Dividend	-	P/FCF	-	EPS past 5Y	16.50%	ROI	-	52W High	-63.81%	Beta	1.62
Dividend %	-	Quick Ratio	7.10	Sales past 5Y	-	Gross Margin	-	52W Low	20.33%	ATR	0.42
Employees	93	Current Ratio	7.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	36.14	Volatility	11.79% 9.58%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	14.60%	Profit Margin	-	Rel Volume	1.47	Prev Close	2.98
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 05 AMC	Payout	-	Avg Volume	1.34M	Price	2.96
Recom	1.70	SMA20	-22.49%	SMA50	-32.50%	SMA200	-38.10%	Volume	1,207,077	Change	-0.67%

Jan-05-21

Downgrade

SVB Leerink

Outperform → Mkt Perform

Mar-27-20

Initiated

Jefferies

Buy

Nov-19-19

Initiated

H.C. Wainwright

Buy

May-30-19

Resumed

Citigroup

Buy

Feb-16-18

Upgrade

Citigroup

Neutral → Buy

Oct-05-17

Initiated

William Blair

Outperform

Apr-03-17

Resumed

Leerink Partners

Outperform

Mar-28-17

Reiterated

H.C. Wainwright

Buy

$10 → $14

Jan-24-17

Upgrade

Citigroup

Sell → Neutral

Jan-05-17

Initiated

H.C. Wainwright

Buy

Oct-25-16

Initiated

Citigroup

Sell

Jul-24-15

Initiated

Citigroup

Buy

Jan-13-21 08:40AM	Implied Volatility Surging for Calithera Biosciences (CALA) Stock Options Zacks
Jan-11-21 05:03PM	INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal Cancers Symposium GlobeNewswire
Jan-06-21 11:14AM	Biotech Stock Roundup: MRNA's COVID-19 Vaccine Updates & Other Pipeline Updates Zacks
Jan-05-21 10:59AM	Calithera (CALA) Plunges as CANTANA Study on Telaglenastat Fails Zacks
07:04AM	Calithera to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference GlobeNewswire
Jan-04-21 12:15PM	Why Calithera Biosciences Stock Is Plunging Today Motley Fool -44.60%
07:00AM	Calithera Biosciences Reports CANTATA Study of Telaglenastat in Renal Cell Carcinoma Did Not Achieve Primary Endpoint GlobeNewswire
Dec-31-20 04:55PM	Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Dec-28-20 11:59PM	Our Take On Calithera Biosciences' (NASDAQ:CALA) CEO Salary Simply Wall St.
Dec-14-20 12:03PM	Is CALA A Good Stock To Buy Now? Insider Monkey
Dec-11-20 08:54AM	Do Options Traders Know Something About Calithera (CALA) Stock We Don't? Zacks
Dec-02-20 07:05AM	Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-11-20 07:01AM	Calithera to Participate in Jefferies Virtual Healthcare Conference and SVB Leerink Oncology 1x1 Day GlobeNewswire
Nov-09-20 07:00AM	Calithera Biosciences Presents New Preclinical Data for CB-668 at Society for Immunotherapy of Cancer (SITC) 2020 Annual Meeting GlobeNewswire
Nov-06-20 04:01PM	Calithera Biosciences Inc (CALA) Q3 2020 Earnings Call Transcript Motley Fool
Nov-05-20 04:06PM	Calithera Biosciences Reports Third Quarter 2020 Financial Results and Recent Highlights GlobeNewswire
03:45PM	Calithera Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Nov-04-20 01:05PM	Calithera Biosciences Announces Expansion of Ongoing Clinical Trial Evaluating Telaglenastat in Combination with palbociclib (IBRANCE®) GlobeNewswire +6.23%
Nov-02-20 04:07PM	Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
08:00AM	Calithera Biosciences Awarded up to $2.4M from Cystic Fibrosis Foundation to Support Clinical Development of Arginase Inhibitor, CB-280 GlobeNewswire
Oct-30-20 07:32AM	What Is The Ownership Structure Like For Calithera Biosciences, Inc. (NASDAQ:CALA)? Simply Wall St.
Oct-29-20 07:01AM	Calithera Biosciences to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 GlobeNewswire
Oct-07-20 08:08AM	Calithera Biosciences CB-280 Arginase Inhibitor Trial in Progress Poster Presented at the North American Cystic Fibrosis 2020 Virtual Conference GlobeNewswire
Oct-02-20 07:01AM	Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-24-20 07:00AM	Calithera Biosciences Initiates KEAPSAKE Randomized Phase 2 Trial of Telaglenastat in Combination with Chemoimmunotherapy to Treat Aggressive Form of Lung Cancer GlobeNewswire
Sep-11-20 09:58AM	2 Strong Buy Healthcare Stocks Under $5 With Massive Upside Potential TipRanks
Sep-04-20 07:00AM	Calithera to Participate in Multiple Upcoming Investor Conferences GlobeNewswire
Sep-02-20 07:01AM	Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-18-20 06:55AM	Companies Like Calithera Biosciences (NASDAQ:CALA) Are In A Position To Invest In Growth Simply Wall St.
Aug-11-20 08:00AM	Calithera Biosciences Inc (CALA) Q2 2020 Earnings Call Transcript Motley Fool -11.78%
Aug-10-20 04:06PM	Calithera Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights GlobeNewswire
Aug-03-20 07:01AM	Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jul-28-20 07:00AM	Calithera Biosciences to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020 GlobeNewswire
Jul-14-20 07:00AM	Calithera Biosciences Appoints Scott Garland to Board of Directors GlobeNewswire
Jul-13-20 07:00AM	Calithera Biosciences Initiates Phase 1b Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis GlobeNewswire
Jul-06-20 08:05AM	Hedge Funds Are Selling Calithera Biosciences Inc (CALA) Insider Monkey
Jul-02-20 07:00AM	Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-02-20 07:00AM	Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-29-20 08:00AM	Calithera Biosciences to Present Telaglenastat KEAPSAKE Trial in Progress Poster at ASCO20 Virtual Annual Meeting GlobeNewswire
May-27-20 07:01AM	Calithera to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire
May-26-20 12:34AM	Edited Transcript of CALA earnings conference call or presentation 7-May-20 9:00pm GMT Thomson Reuters StreetEvents
May-18-20 11:30AM	Has Calithera Biosciences (CALA) Outpaced Other Medical Stocks This Year? Zacks
May-13-20 09:15AM	Is Calithera Biosciences (CALA) Stock a Solid Choice Right Now? Zacks
May-11-20 12:00PM	What Makes Calithera (CALA) a New Buy Stock Zacks
May-08-20 01:01PM	Calithera Biosciences Inc (CALA) Q1 2020 Earnings Call Transcript Motley Fool -6.99%
May-07-20 04:05PM	Calithera Biosciences Reports First Quarter 2020 Financial Results and Recent Highlights GlobeNewswire
May-06-20 07:05AM	Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-01-20 09:57AM	Calithera Biosciences to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020 GlobeNewswire
Apr-30-20 07:01AM	Calithera Biosciences Announces Telaglenastat KEAPSAKE Trial in Progress Abstract Accepted for Presentation at ASCO20 Virtual Annual Meeting GlobeNewswire
Apr-20-20 04:05PM	Calithera Biosciences, Inc. Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares GlobeNewswire
Apr-16-20 12:18AM	Calithera Biosciences, Inc. Prices Public Offering of 5,000,000 shares of Common Stock GlobeNewswire -20.25%
Apr-15-20 04:01PM	Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock GlobeNewswire +17.69%
Apr-14-20 08:48AM	Calithera (CALA) Soars: Stock Adds 9.4% in Session Zacks
07:00AM	Calithera Biosciences Provides Update on Business Operations GlobeNewswire
Apr-13-20 11:14AM	How to Play Speculative Calithera Biosciences TheStreet.com +9.42%
Apr-07-20 09:30AM	Billionaire Steven Cohen Picks up These 2 Stocks on the Dip TipRanks +21.10%
Mar-30-20 05:15PM	Edited Transcript of CALA earnings conference call or presentation 11-Mar-20 9:00pm GMT Thomson Reuters StreetEvents -5.61%
Mar-28-20 09:09AM	Have Insiders Been Buying Calithera Biosciences, Inc. (NASDAQ:CALA) Shares? Simply Wall St.
Mar-11-20 04:10PM	Calithera Biosciences Reports Fourth Quarter 2019 Financial Results and Recent Highlights GlobeNewswire -6.27%
03:00PM	Calithera Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Mar-04-20 07:05AM	Calithera Biosciences to Report Fourth Quarter 2019 Financial Results on Wednesday, March 11, 2020 GlobeNewswire +5.74%
Feb-19-20 07:05AM	Calithera to Participate in the 9th Annual SVB Leerink Global Healthcare Conference GlobeNewswire +7.59%
Jan-30-20 09:38AM	Is Calithera Biosciences, Inc.'s (NASDAQ:CALA) CEO Paid Enough Relative To Peers? Simply Wall St. -6.07%
Jan-13-20 07:07AM	Calithera Biosciences Provides Overview of 2020 Corporate Milestones and Financial Guidance GlobeNewswire
Jan-03-20 07:05AM	Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Dec-13-19 02:46PM	Hedge Funds Are Dumping Calithera Biosciences Inc (CALA) Insider Monkey
Dec-06-19 07:05AM	Data from Investigator-Sponsored Phase 2 Study of Calitheras Telaglenastat with Azacitidine in Myelodysplastic Syndrome to be Presented at ASH Annual Meeting 2019 GlobeNewswire +5.88%
Dec-05-19 07:05AM	Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -5.76%
Dec-04-19 08:20PM	Edited Transcript of CALA earnings conference call or presentation 12-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Dec-02-19 11:38AM	Imagine Owning Calithera Biosciences (NASDAQ:CALA) While The Price Tanked 64% Simply Wall St. -6.50%
Nov-12-19 04:06PM	Calithera Biosciences Reports Third Quarter 2019 Financial Results and Recent Highlights GlobeNewswire
Nov-05-19 08:01AM	Calithera to Present Preclinical Data from IL4I1 and CD73 Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire
Nov-04-19 08:00AM	Calithera Biosciences to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019 GlobeNewswire
Oct-19-19 09:23AM	Read This Before Selling Calithera Biosciences, Inc. (NASDAQ:CALA) Shares Simply Wall St.
Oct-18-19 10:23AM	These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year American City Business Journals
Oct-07-19 09:54AM	Calithera (CALA) Completes Enrollment in Mid-Stage RCC Study Zacks
Oct-03-19 07:05AM	Calithera Biosciences Completes Patient Enrollment in Randomized CANTATA Trial of Telaglenastat and Cabozantinib in Advanced Renal Cell Carcinoma GlobeNewswire +5.43%
Oct-01-19 04:05PM	Calithera Announces Acceptance of Two Abstracts for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire -14.56%
Sep-29-19 10:30AM	New Data Presented at ESMO Congress 2019 from the Arginase Inhibitor INCB001158 Alone and in Combination with Pembrolizumab GlobeNewswire
Sep-28-19 02:30AM	Data From Randomized Phase 2 ENTRATA Study Demonstrate Telaglenastat with Everolimus Improves Progression-Free Survival in Renal Cell Carcinoma GlobeNewswire
Sep-27-19 09:28AM	Calithera Biosciences Enters Oversold Territory Zacks
Sep-26-19 06:05PM	Calithera to Host Webcast Conference Call for Analysts and Investors During European Society for Medical Oncology (ESMO) Congress 2019 GlobeNewswire
12:00PM	Implied Volatility Surging for Calithera (CALA) Stock Options Zacks
Sep-25-19 08:05AM	Calithera to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire
Sep-19-19 10:06AM	Calithera Biosciences, Inc. (NASDAQ:CALA): Is It Growing Too Fast? Simply Wall St.
Sep-09-19 09:38PM	Edited Transcript of CALA earnings conference call or presentation 8-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Aug-28-19 08:00AM	Calithera to Participate in Wells Fargo Healthcare Conference and Citi 14th Annual Biotech Conference GlobeNewswire
Aug-23-19 09:11AM	Is Calithera Biosciences, Inc.'s (NASDAQ:CALA) CEO Pay Justified? Simply Wall St.
Aug-08-19 04:05PM	Calithera Biosciences Reports Second Quarter 2019 Financial Results and Recent Highlights GlobeNewswire
Aug-01-19 07:07AM	Calithera Biosciences to Report Second Quarter 2019 Financial Results on Thursday, August 8, 2019 GlobeNewswire
Jul-24-19 10:40AM	Does Calithera Biosciences, Inc. (NASDAQ:CALA) Have A High Beta? Simply Wall St.
Jul-02-19 08:00AM	Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with Pfizers CDK4/6 Inhibitor Palbociclib GlobeNewswire
Jun-27-19 07:15PM	Calithera Biosciences Inc (CALA) PRESIDENT AND CEO Susan Molineaux Bought $200,208 of Shares GuruFocus.com
Jun-21-19 04:04PM	Calithera Biosciences, Inc. Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares GlobeNewswire -6.27%
Jun-18-19 11:00PM	Calithera Biosciences, Inc. Prices Public Offering of 12,500,000 shares of Common Stock GlobeNewswire -18.28%
01:16PM	Did You Miss Calithera Biosciences's (NASDAQ:CALA) 37% Share Price Gain? Simply Wall St.
Jun-17-19 04:01PM	Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock GlobeNewswire +11.32%
10:08AM	Health Care Digest: Not-so-secret target of new UC-GSK alliance, East Bay toolmaker's big round and more American City Business Journals
10:04AM	Calithera's Kidney Cancer Drug Doubles Progression-Free Survival Vs. Chemotherapy Benzinga
06:00AM	Calithera Achieves Positive Topline Results in Randomized Phase 2 ENTRATA Study of Telaglenastat with Everolimus in Renal Cell Carcinoma GlobeNewswire

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor for the treatment of cystic fibrosis; and CB-708, an orally administered small molecule inhibitor of CD73. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Orford Keith	Chief Medical Officer	Dec 16	Sale	6.00	2,447	14,682	11,094	Dec 18 05:00 PM
BVF PARTNERS L P/IL	10% Owner	May 21	Sale	6.00	2,283,598	13,701,588	480,432	May 26 05:52 PM
Wong Stephanie	SR. VP, FINANCE & SECRETARY	Apr 15	Sale	8.00	5,000	40,000	30,082	Apr 17 04:05 PM
Orford Keith	Chief Medical Officer	Feb 20	Sale	8.00	3,021	24,168	8,541	Feb 24 04:05 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience